Nkarta (NASDAQ:NKTX) Given New $36.00 Price Target at HC Wainwright

Nkarta (NASDAQ:NKTXGet Rating) had its price objective increased by equities researchers at HC Wainwright from $25.00 to $36.00 in a research report issued on Monday, The Fly reports. HC Wainwright’s price objective points to a potential upside of 123.88% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Nkarta in a research report on Tuesday, March 29th. Zacks Investment Research upgraded shares of Nkarta from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Tuesday, April 5th. William Blair began coverage on shares of Nkarta in a research report on Thursday, January 6th. They set an “outperform” rating and a $35.00 price objective on the stock. Finally, Raymond James began coverage on shares of Nkarta in a research report on Friday, March 11th. They issued an “outperform” rating and a $17.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Nkarta has an average rating of “Buy” and a consensus target price of $50.56.

Shares of Nkarta stock traded up $8.31 on Monday, hitting $16.08. 1,693,384 shares of the company traded hands, compared to its average volume of 211,290. The firm’s 50-day simple moving average is $10.13 and its 200 day simple moving average is $13.14. The company has a market cap of $530.66 million, a P/E ratio of -6.18 and a beta of 1.27. Nkarta has a 12-month low of $7.55 and a 12-month high of $40.64.

Nkarta (NASDAQ:NKTXGet Rating) last posted its quarterly earnings data on Thursday, March 17th. The company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.06. Research analysts forecast that Nkarta will post -3.07 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in Nkarta by 0.6% in the 3rd quarter. BlackRock Inc. now owns 1,361,219 shares of the company’s stock worth $37,854,000 after purchasing an additional 8,393 shares during the period. Deep Track Capital LP purchased a new position in shares of Nkarta in the fourth quarter valued at about $19,409,000. Wasatch Advisors Inc. increased its position in shares of Nkarta by 17.6% in the fourth quarter. Wasatch Advisors Inc. now owns 631,602 shares of the company’s stock valued at $9,695,000 after acquiring an additional 94,678 shares during the period. Rock Springs Capital Management LP increased its position in shares of Nkarta by 1.0% in the third quarter. Rock Springs Capital Management LP now owns 503,148 shares of the company’s stock valued at $13,993,000 after acquiring an additional 5,200 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Nkarta by 851.7% in the third quarter. Goldman Sachs Group Inc. now owns 233,688 shares of the company’s stock valued at $6,499,000 after acquiring an additional 209,133 shares during the period. Institutional investors own 71.46% of the company’s stock.

Nkarta Company Profile (Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Featured Articles

The Fly logo

Analyst Recommendations for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.